Vertex Pharmaceuticals (VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes. That rise was slightly more pronounced than the S&P 500 index's 2.5% increase.
One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact.
According to reports, Merle's update was based on surveys with medical professionals indicating that the company's next-generation Journavx pain relief treatment is seeing a notable increase in demand.
The second of the pair was part of a broader dive into the current state of pharmaceutical stocks by investment bank Cantor Fitzgerald. The firm presented its new rankings for some of the top names in the field, and flagged Vertex as an overweight (i.e., buy) at $535 per share.
With that tag, Vertex joined sector luminaries such as Zepbound developer Eli Lilly and AbbVie as being buy candidates, in the researcher's view. Cantor Fitzgerald was more bearish on others, like Pfizer and Amgen, which it rated only neutral.
Vertex is appealing simply by virtue of its business strategy; it concentrates on afflictions with high unmet needs. It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates. I think this stock is well worth a look as a somewhat offbeat way to play the biotech and pharma spaces.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。